Oncology

AI Integration Improves Lung Cancer MDT Workflow at ATS 2026

Integrating AI for lung cancer prediction into multidisciplinary team workflows demonstrates operational improvements and potential for enhanced patient stratification.

ATS 2026: Lung Cancer Management Advances in Targeted Therapy

ATS 2026 highlights evolving lung cancer management, focusing on precision medicine and novel targeted therapies for improved patient outcomes.

MAVEs Inform Variant Interpretation in Clinical Oncology Practice

Multiplex Assays of Variant Effects (MAVEs) offer a systematic approach to interpreting genetic variants in oncology, addressing current limitations in variant classification.

AI in Oncology: Practical Applications Transforming Cancer Care

AI integration in oncology is moving beyond theoretical promise to deliver tangible benefits in diagnosis, treatment planning, and patient management.

DNA Methylation Patterns Emerge as Sarcoma Biomarkers

Sarcomas present diagnostic and therapeutic challenges due to their heterogeneous nature. DNA methylation profiling may enhance early diagnosis and personalized treatment.

HTAN Decodes Tumor Evolution: Ecological Perspective at AACR2026

Understanding tumor evolution is critical for effective cancer therapy. The Human Tumor Atlas Network (HTAN) provides an ecological and evolutionary framework.

Next-Gen Extracellular Vesicles: Biomarkers, Targets, Deliverables in Oncology

Extracellular vesicles (EVs) and particles (EPs) offer new avenues for cancer diagnosis, prognosis, and therapy. Their role as biomarkers and drug delivery systems is expanding.

NK Cell Immunotherapy: Biology to Clinic at AACR 2026

Natural killer (NK) cell-based immunotherapies are emerging as a promising cancer treatment strategy, with ongoing clinical trials exploring their efficacy.

Cancer Therapies Induce Lifespan Comorbidities: ACCR 2026 Review

Cancer therapies, while life-saving, induce significant long-term comorbidities across all age groups, necessitating integrated survivorship care.

Early Breast Cancer at ASCO 2026: Trials to Watch

ASCO 2026 is expected to bring pivotal data on adjuvant and neoadjuvant strategies in early breast cancer. Here is what clinicians should watch for.